Clicky

Hikma Pharmaceutical(HKMPF)

Description: Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.


Keywords: Pain Diabetes Pain Management Suspension Dosage Form Kma Licensed Products Nasal Spray Osage Cardiovascular Products Oncology Products Generic Products Injectable Products Anti Infective Products Generic Injectable Products Hikma Pharmaceuticals

Home Page: www.hikma.com

1 New Burlington Place
London, W1S 2HR
United Kingdom
Phone: 44 20 7399 2760


Officers

Name Title
Engineer Said Samih Taleb Darwazah Executive Chairman
Mr. Riad Ali Mishlawi CEO & Director
Mr. Mazen Samih Taleb Darwazah Executive Vice Chairman & President of MENA
Mr. Khalid Waleed Hosny Al Nabilsi CPA Chief Financial Officer
Patricia Bousfield Chief Information Officer
Mr. Guy Featherstone Associate Director of Investor Relations
Mr. Samuel Park General Counsel
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Executive Vice President of Corporate Development and M&A
Mr. Hussein Omar Arkhagha Chief People Officer
Ms. Susan Ringdal Executive Vice President of Strategic Planning & Global Affairs

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 10.9769
Trailing PE: 29.2588
Price-to-Book MRQ: 2.5106
Price-to-Sales TTM: 1.8328
IPO Date:
Fiscal Year End: December
Full Time Employees: 9100
Back to stocks